![BloodSafe eLearning Australia podcasts artwork](https://is4-ssl.mzstatic.com/image/thumb/Podcasts124/v4/ed/17/c8/ed17c8fc-b693-16b2-e2dd-1e82b2ae941d/mza_7104435340744307095.jpg/100x100bb.jpg)
Haemolytic Disease of the Fetus and Newborn (HDFN)
BloodSafe eLearning Australia podcasts
English - September 14, 2023 08:06 - 26 minutes - 48.7 MBMedicine Health & Fitness bleeding patientbloodmanagement pbm tranexamicacid trauma Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Transfusion and Patient Blood Management – a haematologist’s perspective
The incidence of HDFN due to RhD has fallen substantially since the introduction of RhD immunoglobulin. However, the identification of a pregnant woman at risk of RhD senstitisation is extremely important to ensure that she receives RhD immunoglobulin appropriately.
Here, Dr Helen Savoia talks about HDFN, sensitising events and the management of RhD negative women with regard to laboratory testing, surveillance and administration of RhD immunoglobulin in line with the ‘Prophylactic use of RhD immunoglobulin in pregnancy care’ guideline available at www.blood.gov.au.